Q32 Bio (QTTB) Debt Ratio (2023 - 2026)

Q32 Bio (QTTB) posted quarterly Debt Ratio of 0.13 for Q1 2026, down 20.04% year-over-year from 0.16 in Q1 2025, and down 18.27% quarter-over-quarter from 0.16 in Q4 2025.

Q32 Bio (QTTB) Debt Ratio (2023 - 2026) Analysis & Trends

Q32 Bio's Debt Ratio history runs 4 years deep, the most recent figure standing at 0.13 for Q1 2026.

  • In Q1 2026, Debt Ratio fell 20.04% year-over-year to 0.13; the TTM figure through Mar 2026 stood at 0.13 (down 20.04% YoY), while the FY2025 annual figure was 0.16, up 14.67% from the prior year.
  • Debt Ratio for Q1 2026 stood at 0.13, down from 0.16 in the prior quarter.
  • The five-year high for Debt Ratio was 0.19 in Q3 2025, with the low at 0.08 in Q1 2024.
  • The 4-year median for Debt Ratio is 0.13 (2024), against an average of 0.14.
  • The sharpest annual moves came in 2025 and 2026: Debt Ratio jumped 95.94% in 2025, then fell 20.04% in 2026.
  • Q32 Bio's Debt Ratio stood at 0.12 in 2023, then climbed by 18.13% to 0.14 in 2024, then gained by 14.67% to 0.16 in 2025, then fell by 18.27% to 0.13 in 2026.
  • Business Quant data shows QTTB's Debt Ratio at 0.13 in Q1 2026, 0.16 in Q4 2025, and 0.19 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.05
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.12
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.47
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.26
10 Q32 Bio 359.61 Mn 253.31 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 0.13
Dec 31, 2025 0.16
Sep 30, 2025 0.19
Jun 30, 2025 0.19
Mar 31, 2025 0.16
Dec 31, 2024 0.14
Sep 30, 2024 0.12
Jun 30, 2024 0.10
Mar 31, 2024 0.08
Dec 31, 2023 0.12